Biocept Overview
- Founded
-
1997
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
BIOC
- Share Price
-
$1.40
- (As of Friday Closing)
Biocept General Information
Description
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Contact Information
- 9955 Mesa Rim Road
- San Diego, CA 92121
- United States
Biocept Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.40 | $1.42 | $0.80 - $29.18 | 2.63M | 1.9M | -$48.35 |
Biocept Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 6,587 | 3,282 | 38,818 | 45,328 |
| Revenue | 2,269 | 25,858 | 61,249 | 27,461 |
| EBITDA | (28,709) | (30,241) | (879) | (16,570) |
| Net Income | (30,608) | (32,087) | (2,824) | (17,807) |
| Total Assets | 22,103 | 30,873 | 60,417 | 47,453 |
| Total Debt | 11,591 | 12,109 | 12,673 | 12,229 |
Biocept Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biocept Comparisons
Industry
Financing
Details
000000
000000
Biocept Competitors (31)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CirculoGene | Venture Capital-Backed | Birmingham, AL | 00 | 000.00 | 0000000000 0 | 000.00 |
| 00000000 00000000 | Formerly VC-backed | Waltham, MA | 00 | 0000 | 00000000000 | 0000 |
| 000000 000000 | Venture Capital-Backed | South Plainfield, NJ | 00 | 00000 00000 | ||
| 00000000 000000000 | Private Equity-Backed | Wuxi, China | 00000 | 00000000 | 00000 | |
| 00000 00000000 | Corporate Backed or Acquired | Aliso Viejo, CA | 000 | 000000&0 |
Biocept Patents
Biocept Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4244236-A1 | Pathogen inactivating and nucleic acid stabilization media for microorganism collection and transport | Pending | 11-Nov-2020 | 00000000 | |
| AU-2020201291-B2 | Methods for detecting nucleic acid sequence variants | Active | 04-May-2011 | 0000000000 | 0 |
| AU-2012250516-A1 | Methods for detecting nucleic acid sequence variants | Active | 04-May-2011 | 0000000000 | |
| AU-2012250516-B2 | Methods for detecting nucleic acid sequence variants | Active | 04-May-2011 | 0000000000 | |
| AU-2017268486-B2 | Methods for detecting nucleic acid sequence variants | Active | 04-May-2011 | C12Q1/6858 |
Biocept Executive Team (21)
Biocept Board Members (20)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bruce Gerhardt | Self | Board Member | 000 0000 |
| David Hale | Self | Chairman of the Board | 000 0000 |
| Faye Wilson | Biocept | Chair of Audit Committee & Board Member | 000 0000 |
| Ivor Royston MD | Self | Board Member | 000 0000 |
| Linda Rubinstein | Self | Board Member | 000 0000 |
Biocept Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
